Q/C TECHNOLOGIES, INC. — Director's Dealing 2022

Dec 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MyMD Pharmaceuticals, Inc. (MYMD)
CIK: 0001321834
Period of Report: 2022-12-08

Reporting Person: Rivard Paul (EVP of Operations, GC)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-08	Common stock	P	10000	$1.53	Acquired	225000	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.53, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.